Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 12,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome, Cowden Syndrome, Bannayan Syndrome, Bannayan Zonana Syndrome, Polyposis
Interventions: Sirolimus; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Actinic Keratosis
Interventions: Metvix-PDT, Vehicle-PDT; Combination Product
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Ciliary Dyskinesia
Interventions: There is no intervention; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 0 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Not listed
Lead sponsor: John F. Foley, MD; Other
Eligibility: 18 Years to 68 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza
Interventions: CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Bonvadis® (NWBOT), Clostridial Collagenase Ointment; Device
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: North Port, Florida • Palm Coast, Florida • South Miami, Florida + 7 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ALZT-OP1a (cromolyn); Drug
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • New York, New York + 2 more

Conditions: Multiple Sclerosis
Interventions: Factors that influence compliance; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cervicogenic Headache, Neck Pain, Whiplash, Kyphotic and Reversed Cervical Curves
Interventions: Not listed
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Mitiperstat (AZD4831), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Newport Beach, California • Clearwater, Florida • DeLand, Florida + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anaheim, California • Chula Vista, California • South Miami, Florida

Conditions: Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: DCI 1020; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 0 Years to 89 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Gamma-Secretase Inhibitor RO4929097, Hematopoietic Stem Cell Mobilization, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Fountain Valley, California • Mather, California • Sacramento, California + 28 more

Conditions: Psoriasis Vulgaris
Interventions: PTH (1-34) Gel / Placebo Gel; Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more

Conditions: Single Sided Deafness, Conductive Hearing Loss
Interventions: Not listed
Lead sponsor: Sonitus Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Newport Beach, California + 10 more

Conditions: Obesity, Hypertension, Diabetes Mellitus, Type 2
Interventions: Overstitch Endoscopic Suture System, Lifestyle Intervention; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 65 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Orlando, Florida • Chicago, Illinois • Evanston, Illinois + 6 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrevus; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more

Conditions: Moderate to Severe Traumatic Brain Injury
Interventions: Fresh Frozen Plasma (FFP); Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Sirolimus for Cowden Syndrome With Colon Polyposis

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

PCD New Gene Discovery

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

SoundBite Hearing System Long Term Multi Site Patient Use Study

Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial